Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.27 -2.1%	$0.27	$0.20 ▼ $1.48	$71.19M	2.18	1.63 million shs	314,380 shs
AGEN Agenus	$7.06 +19.3%	$4.37	$1.38 ▼ $18.74	$193.56M	1.51	730,222 shs	6.78 million shs
ALEC Alector	$1.61 -6.4%	$1.38	$0.87 ▼ $6.78	$160.98M	0.74	837,051 shs	254,301 shs
CLLS Cellectis	$1.59 -3.6%	$1.49	$1.10 ▼ $2.43	$88.37M	2.91	142,976 shs	17,239 shs
PASG Passage Bio	$0.40 +0.9%	$0.38	$0.26 ▼ $1.33	$24.92M	1.67	388,217 shs	346,982 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-0.54%	+9.28%	-1.08%	+23.39%	-76.95%
AGEN Agenus	+14.29%	-0.17%	+10.24%	+248.24%	-61.31%
ALEC Alector	+4.24%	+16.61%	+8.18%	+81.05%	-65.74%
CLLS Cellectis	+1.54%	+4.10%	+17.02%	+14.58%	-15.38%
PASG Passage Bio	-9.86%	-13.77%	-17.10%	+9.66%	-51.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.429 of 5 stars	3.1	5.0	0.0	2.1	0.8	0.0
AGEN Agenus	4.3652 of 5 stars	3.2	4.0	4.6	2.5	1.7	0.6
ALEC Alector	4.1105 of 5 stars	3.1	3.0	4.5	2.6	2.5	0.0
CLLS Cellectis	3.1593 of 5 stars	3.5	3.0	0.0	2.6	2.5	0.6
PASG Passage Bio	2.8264 of 5 stars	3.5	3.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	402.48% Upside
AGEN Agenus	2.33	Hold	$14.00	103.34% Upside
ALEC Alector	2.14	Hold	$4.00	147.68% Upside
CLLS Cellectis	3.00	Buy	$4.00	146.15% Upside
PASG Passage Bio	3.00	Buy	$7.50	1,689.98% Upside

Current Analyst Ratings Breakdown

Latest ADAP, ALEC, PASG, CLLS, and AGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/13/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/13/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/9/2025	ALEC Alector	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $10.00
4/30/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.40	N/A	N/A	$0.05 per share	5.38
AGEN Agenus	$99.52M	1.90	N/A	N/A	($13.06) per share	-0.53
ALEC Alector	$100.56M	1.61	N/A	N/A	$1.29 per share	1.25
CLLS Cellectis	$49.22M	1.83	N/A	N/A	$2.36 per share	0.69
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
AGEN Agenus	-$227.21M	-$8.67	N/A	N/A	N/A	-196.12%	N/A	-82.33%	8/6/2025 (Estimated)
ALEC Alector	-$119.05M	-$1.26	N/A	N/A	N/A	-139.74%	-100.58%	-25.15%	8/6/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)

Latest ADAP, ALEC, PASG, CLLS, and AGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ALEC Alector	-$0.45	N/A	N/A	N/A	$2.76 million	N/A
8/5/2025	N/A	CLLS Cellectis	-$0.15	N/A	N/A	N/A	$10.07 million	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
ALEC Alector	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
AGEN Agenus	N/A	0.11	0.11
ALEC Alector	0.10	3.34	3.34
CLLS Cellectis	0.44	1.67	1.67
PASG Passage Bio	N/A	3.74	3.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
AGEN Agenus	61.46%
ALEC Alector	85.83%
CLLS Cellectis	63.90%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
AGEN Agenus	5.50%
ALEC Alector	9.10%
CLLS Cellectis	16.41%
PASG Passage Bio	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
AGEN Agenus	440	27.42 million	25.91 million	Optionable
ALEC Alector	270	99.99 million	90.89 million	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
PASG Passage Bio	130	62.15 million	59.04 million	Optionable

ADAP, ALEC, PASG, CLLS, and AGEN Headlines

Recent News About These Companies

Passage Bio Announces 1-for-20 Reverse Stock Split

July 10 at 7:00 AM | globenewswire.com

Passage Bio, Inc. (PASG) Income Statement - Yahoo Finance

July 1, 2025 | finance.yahoo.com

PASG Passage Bio, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 Shares

June 27, 2025 | insidertrades.com

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

June 23, 2025 | globenewswire.com

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025 | msn.com

Passage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestre

May 13, 2025 | zonebourse.comZ

PASSAGE BIO, INC. : Wedbush persiste à l'achat

May 13, 2025 | zonebourse.comZ

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

May 13, 2025 | globenewswire.com

Insider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of Stock

April 25, 2025 | insidertrades.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 Shares

April 18, 2025 | insidertrades.com

OrbiMed Advisors vend des actions de Passage Bio pour 49.704$

April 18, 2025 | fr.investing.com

L’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marché

April 8, 2025 | fr.investing.com

L’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$

March 31, 2025 | fr.investing.com

L'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$

March 14, 2025 | fr.investing.com

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

March 7, 2025 | zacks.com

PASSAGE BIO, INC. : Chardan Research reste à l'achat

March 5, 2025 | zonebourse.comZ

L’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$

March 5, 2025 | fr.investing.com

Passage Bio price target lowered to $6 from $7 at Chardan

March 5, 2025 | markets.businessinsider.com

Passage Bio publie ses résultats du quatrième trimestre et de l'année 2024.

March 4, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, ALEC, PASG, CLLS, and AGEN Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.27 -0.01 (-2.08%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 +0.00 (+0.15%)

As of 04:37 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Agenus NASDAQ:AGEN

$7.06 +1.14 (+19.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.04 -0.02 (-0.28%)

As of 04:39 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Alector NASDAQ:ALEC

$1.61 -0.11 (-6.40%)

Closing price 04:00 PM Eastern

Extended Trading

$1.61 0.00 (0.00%)

As of 04:10 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Cellectis NASDAQ:CLLS

$1.62 -0.04 (-2.12%)

As of 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Passage Bio NASDAQ:PASG

$0.40 +0.00 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$0.47 +0.07 (+17.74%)

As of 04:39 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time